{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:49:09Z","timestamp":1791355749463,"version":"4.3.1"},"reference-count":99,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100005847","name":"Health and Medical Research Fund","doi-asserted-by":"publisher","award":["RRG-15"],"award-info":[{"award-number":["RRG-15"]}],"id":[{"id":"10.13039\/501100005847","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Government of Hong Kong SAR"},{"DOI":"10.13039\/100000060","name":"NIAID","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NIH USA"},{"name":"AXA Research Award"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Virology"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.coviro.2016.05.004","type":"journal-article","created":{"date-parts":[[2016,6,24]],"date-time":"2016-06-24T00:17:08Z","timestamp":1466727428000},"page":"126-134","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":60,"special_numbering":"C","title":["Current and novel antiviral strategies for influenza infection"],"prefix":"10.1016","volume":"18","author":[{"given":"Hui-Ling","family":"Yen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coviro.2016.05.004_bib0500","doi-asserted-by":"crossref","first-page":"28403","DOI":"10.1074\/jbc.R110.129809","article-title":"Influenza hemagglutinin and neuraminidase membrane glycoproteins","volume":"285","author":"Gamblin","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1016\/j.coviro.2016.05.004_bib0505","doi-asserted-by":"crossref","first-page":"e1002276","DOI":"10.1371\/journal.ppat.1002276","article-title":"Multidrug resistant 2009 A\/H1N1 influenza clinical isolate with a neuraminidase I223R mutation retains its virulence and transmissibility in ferrets","volume":"7","author":"van der Vries","year":"2011","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2016.05.004_bib0510","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1146\/annurev.biochem.69.1.531","article-title":"Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin","volume":"69","author":"Skehel","year":"2000","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.coviro.2016.05.004_bib0515","doi-asserted-by":"crossref","first-page":"207","DOI":"10.4161\/rna.8.2.14513","article-title":"The influenza virus RNA synthesis machine: advances in its structure and function","volume":"8","author":"Resa-Infante","year":"2011","journal-title":"RNA Biol"},{"key":"10.1016\/j.coviro.2016.05.004_bib0520","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.virusres.2009.05.010","article-title":"Influenza virus morphogenesis and budding","volume":"143","author":"Nayak","year":"2009","journal-title":"Virus Res"},{"key":"10.1016\/j.coviro.2016.05.004_sbref0525","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/S1473-3099(14)70821-7","article-title":"Antiviral combinations for severe influenza","volume":"14","author":"Dunning","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.coviro.2016.05.004_bib0530","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1353\/bhm.2002.0022","article-title":"Updating the accounts: global mortality of the 1918\u20131920 \u201cSpanish\u201d influenza pandemic","volume":"76","author":"Johnson","year":"2002","journal-title":"Bull Hist Med"},{"key":"10.1016\/j.coviro.2016.05.004_bib0535","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.bbamem.2010.04.015","article-title":"Influenza M2 proton channels","volume":"1808","author":"Pielak","year":"2011","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.coviro.2016.05.004_bib0540","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1056\/NEJM198912213212502","article-title":"Emergence and apparent transmission of rimantadine-resistant influenza A virus in families","volume":"321","author":"Hayden","year":"1989","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coviro.2016.05.004_bib0545","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1086\/518936","article-title":"Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide","volume":"196","author":"Deyde","year":"2007","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2016.05.004_bib0550","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/S0140-6736(05)67338-2","article-title":"Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern","volume":"366","author":"Bright","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.coviro.2016.05.004_bib0555","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.3851\/IMP1678","article-title":"Comprehensive assessment of 2009 pandemic influenza A (H1N1) virus drug susceptibility in vitro","volume":"15","author":"Gubareva","year":"2010","journal-title":"Antivir Ther"},{"key":"10.1016\/j.coviro.2016.05.004_bib0560","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002745.pub4","article-title":"Amantadine and rimantadine for influenza A in children and the elderly","volume":"11","author":"Alves Galvao","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.coviro.2016.05.004_bib0565","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/j.1460-2075.1992.tb05026.x","article-title":"The 2.2A resolution crystal structure of influenza B neuraminidase and its complex with sialic acid","volume":"11","author":"Burmeister","year":"1992","journal-title":"EMBO J"},{"key":"10.1016\/j.coviro.2016.05.004_bib0570","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1750-2659.2011.00304.x","article-title":"Influenza neuraminidase","volume":"6","author":"Air","year":"2012","journal-title":"Influenza Other Respir Viruses"},{"key":"10.1016\/j.coviro.2016.05.004_bib0575","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/nature05114","article-title":"The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design","volume":"443","author":"Russell","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2016.05.004_bib0580","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1128\/JVI.67.6.2972-2980.1993","article-title":"Sequence and structure alignment of paramyxovirus hemagglutinin-neuraminidase with influenza virus neuraminidase","volume":"67","author":"Colman","year":"1993","journal-title":"J Virol"},{"issue":"Suppl 2","key":"10.1016\/j.coviro.2016.05.004_bib0585","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1016\/S0264-410X(02)00132-9","article-title":"Neuraminidase inhibitors as antivirals","volume":"20","author":"Colman","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2016.05.004_bib0590","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/0042-6822(74)90080-4","article-title":"Inhibition of neuraminidase activity by derivatives of 2-deoxy-2,3-dehydro-N-acetylneuraminic acid","volume":"58","author":"Meindl","year":"1974","journal-title":"Virology"},{"key":"10.1016\/j.coviro.2016.05.004_bib0595","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1002\/pro.5560031007","article-title":"Influenza virus neuraminidase: structure, antibodies, and inhibitors","volume":"3","author":"Colman","year":"1994","journal-title":"Protein Sci"},{"key":"10.1016\/j.coviro.2016.05.004_bib0600","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/303041a0","article-title":"Structure of the catalytic and antigenic sites in influenza virus neuraminidase","volume":"303","author":"Colman","year":"1983","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2016.05.004_bib0605","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/303035a0","article-title":"Structure of the influenza virus glycoprotein antigen neuraminidase at 2.9A resolution","volume":"303","author":"Varghese","year":"1983","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2016.05.004_bib0610","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/nrd2400","article-title":"The war against influenza: discovery and development of sialidase inhibitors","volume":"6","author":"von Itzstein","year":"2007","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.coviro.2016.05.004_bib0615","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/363418a0","article-title":"Rational design of potent sialidase-based inhibitors of influenza virus replication","volume":"363","author":"von Itzstein","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2016.05.004_bib0620","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1021\/ja963036t","article-title":"Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity","volume":"119","author":"Kim","year":"1997","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.coviro.2016.05.004_bib0625","doi-asserted-by":"crossref","first-page":"3482","DOI":"10.1021\/jm0002679","article-title":"BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design","volume":"43","author":"Babu","year":"2000","journal-title":"J Med Chem"},{"key":"10.1016\/j.coviro.2016.05.004_bib0630","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0969-2126(98)00075-6","article-title":"Drug design against a shifting target: a structural basis for resistance to inhibitors in a variant of influenza virus neuraminidase","volume":"6","author":"Varghese","year":"1998","journal-title":"Structure"},{"issue":"Suppl 1","key":"10.1016\/j.coviro.2016.05.004_sbref0635","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/irv.12047","article-title":"Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance","volume":"7","author":"McKimm-Breschkin","year":"2013","journal-title":"Influenza Other Respir Viruses"},{"key":"10.1016\/j.coviro.2016.05.004_bib0640","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1517\/14656566.2015.1066336","article-title":"Peramivir: an intravenous neuraminidase inhibitor","volume":"16","author":"McLaughlin","year":"2015","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.coviro.2016.05.004_bib0645","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1128\/AAC.01311-09","article-title":"Laninamivir prodrug CS-8958, a long-acting neuraminidase inhibitor, shows superior anti-influenza virus activity after a single administration","volume":"54","author":"Kubo","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2016.05.004_bib0650","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1128\/AAC.00333-08","article-title":"CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity","volume":"53","author":"Yamashita","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2016.05.004_sbref0655","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1126\/science.1232552","article-title":"Mechanism-based covalent neuraminidase inhibitors with broad-spectrum influenza antiviral activity","volume":"340","author":"Kim","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.coviro.2016.05.004_bib0660","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.antiviral.2014.07.001","article-title":"Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2012\u20132013","volume":"110","author":"Meijer","year":"2014","journal-title":"Antivir Res"},{"key":"10.1016\/j.coviro.2016.05.004_bib0665","doi-asserted-by":"crossref","first-page":"e1002249","DOI":"10.1371\/journal.ppat.1002249","article-title":"Structural and functional analysis of laninamivir and its octanoate prodrug reveals group specific mechanisms for influenza NA inhibition","volume":"7","author":"Vavricka","year":"2011","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2016.05.004_bib0670","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.bbrc.2012.10.095","article-title":"A single E105K mutation far from the active site of influenza B virus neuraminidase contributes to reduced susceptibility to multiple neuraminidase-inhibitor drugs","volume":"429","author":"Fujisaki","year":"2012","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.coviro.2016.05.004_bib0675","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.antiviral.2015.02.003","article-title":"Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2013\u20132014","volume":"117","author":"Takashita","year":"2015","journal-title":"Antivir Res"},{"key":"10.1016\/j.coviro.2016.05.004_bib0680","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1038\/4371108a","article-title":"Avian flu: isolation of drug-resistant H5N1 virus","volume":"437","author":"Le","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2016.05.004_bib0685","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(04)16934-1","article-title":"Resistant influenza A viruses in children treated with oseltamivir: descriptive study","volume":"364","author":"Kiso","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.coviro.2016.05.004_bib0690","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1093\/infdis\/jiu244","article-title":"A novel I221L substitution in neuraminidase confers high-level resistance to oseltamivir in influenza B viruses","volume":"210","author":"Escuret","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2016.05.004_bib0695","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1086\/314440","article-title":"Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus","volume":"178","author":"Gubareva","year":"1998","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2016.05.004_bib0700","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1086\/500465","article-title":"Recovery of drug-resistant influenza virus from immunocompromised patients: a case series","volume":"193","author":"Ison","year":"2006","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2016.05.004_bib0705","unstructured":"WHO: Summary of Neuraminidase Amino Acid Substitutions Associated with Reduced Inhibition by Neuraminidase Inhibitors (NAI) (http:\/\/www.who.int\/influenza\/gisrs_laboratory\/antiviral_susceptibility\/avwg2014_nai_substitution_table.pdf?ua=1)"},{"issue":"Suppl 1","key":"10.1016\/j.coviro.2016.05.004_bib0710","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1086\/591851","article-title":"Developing new antiviral agents for influenza treatment: what does the future hold?","volume":"48","author":"Hayden","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.coviro.2016.05.004_bib0715","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1098\/rstb.2001.1002","article-title":"Treatment of influenza with neuraminidase inhibitors: virological implications","volume":"356","author":"Roberts","year":"2001","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"10.1016\/j.coviro.2016.05.004_bib0720","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1093\/cid\/cis1220","article-title":"Global assessment of resistance to neuraminidase inhibitors, 2008\u20132011: the Influenza Resistance Information Study (IRIS)","volume":"56","author":"Whitley","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.coviro.2016.05.004_bib0725","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/00006454-200102000-00002","article-title":"Oral oseltamivir treatment of influenza in children","volume":"20","author":"Whitley","year":"2001","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.coviro.2016.05.004_bib0730","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1086\/508777","article-title":"Characterization of multidrug-resistant influenza A\/H3N2 viruses shed during 1 year by an immunocompromised child","volume":"43","author":"Baz","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.coviro.2016.05.004_bib0735","doi-asserted-by":"crossref","first-page":"7188","DOI":"10.1128\/AAC.03667-14","article-title":"Multiple influenza A (H3N2) mutations conferring resistance to neuraminidase inhibitors in a bone marrow transplant recipient","volume":"58","author":"Eshaghi","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2016.05.004_bib0740","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1093\/cid\/cit725","article-title":"The natural history of influenza infection in the severely immunocompromised vs nonimmunocompromised hosts","volume":"58","author":"Memoli","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.coviro.2016.05.004_bib0745","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jcv.2013.06.003","article-title":"Different drug-resistant influenza A(H3N2) variants in two immunocompromised patients treated with oseltamivir during the 2011\u20132012 influenza season in Italy","volume":"58","author":"Piralla","year":"2013","journal-title":"J Clin Virol"},{"key":"10.1016\/j.coviro.2016.05.004_bib0750","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1056\/NEJM200302273480923","article-title":"Prolonged shedding of multidrug-resistant influenza A virus in an immunocompromised patient","volume":"348","author":"Weinstock","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coviro.2016.05.004_bib0755","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1093\/infdis\/jiv245","article-title":"Emergence of multidrug-resistant influenza A(H1N1)pdm09 virus variants in an immunocompromised child treated with oseltamivir and zanamivir","volume":"212","author":"Tamura","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2016.05.004_sbref0760","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1126\/science.1187816","article-title":"Permissive secondary mutations enable the evolution of influenza oseltamivir resistance","volume":"328","author":"Bloom","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.coviro.2016.05.004_bib0765","doi-asserted-by":"crossref","first-page":"5029","DOI":"10.1038\/ncomms6029","article-title":"Epistatic interactions between neuraminidase mutations facilitated the emergence of the oseltamivir-resistant H1N1 influenza viruses","volume":"5","author":"Duan","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.coviro.2016.05.004_bib0770","doi-asserted-by":"crossref","first-page":"e1002431","DOI":"10.1371\/journal.ppat.1002431","article-title":"Role of permissive neuraminidase mutations in influenza A\/Brisbane\/59\/2007-like (H1N1) viruses","volume":"7","author":"Abed","year":"2011","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2016.05.004_bib0775","doi-asserted-by":"crossref","first-page":"597","DOI":"10.3851\/IMP1804","article-title":"Neuraminidase of 2007\u20132008 influenza A(H1N1) viruses shows increased affinity for sialic acids due to the D344 N substitution","volume":"16","author":"Rameix-Welti","year":"2011","journal-title":"Antivir Ther"},{"key":"10.1016\/j.coviro.2016.05.004_bib0780","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/jac\/dkg007","article-title":"Early administration of oral oseltamivir increases the benefits of influenza treatment","volume":"51","author":"Aoki","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.coviro.2016.05.004_sbref0785","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1183\/09031936.00169714","article-title":"Neuraminidase inhibitors, superinfection and corticosteroids affect survival of influenza patients","volume":"45","author":"Lee","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.coviro.2016.05.004_bib0790","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S2213-2600(14)70041-4","article-title":"Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data","volume":"2","author":"Muthuri","year":"2014","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.coviro.2016.05.004_sbref0795","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/S0140-6736(14)62449-1","article-title":"Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials","volume":"385","author":"Dobson","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.coviro.2016.05.004_sbref0800","doi-asserted-by":"crossref","first-page":"g2545","DOI":"10.1136\/bmj.g2545","article-title":"Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments","volume":"348","author":"Jefferson","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.coviro.2016.05.004_bib0805","doi-asserted-by":"crossref","first-page":"g2547","DOI":"10.1136\/bmj.g2547","article-title":"Zanamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments","volume":"348","author":"Heneghan","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.coviro.2016.05.004_bib0810","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.antiviral.2013.09.015","article-title":"Favipiravir (T-705), a novel viral RNA polymerase inhibitor","volume":"100","author":"Furuta","year":"2013","journal-title":"Antivir Res"},{"key":"10.1016\/j.coviro.2016.05.004_bib0815","doi-asserted-by":"crossref","first-page":"5202","DOI":"10.1128\/AAC.00649-13","article-title":"Mechanism of action of T-705 ribosyl triphosphate against influenza virus RNA polymerase","volume":"57","author":"Sangawa","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2016.05.004_bib0820","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1128\/JVI.02346-12","article-title":"T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro","volume":"87","author":"Baranovich","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2016.05.004_bib0825","doi-asserted-by":"crossref","first-page":"e03679","DOI":"10.7554\/eLife.03679","article-title":"Favipiravir elicits antiviral mutagenesis during virus replication in vivo","volume":"3","author":"Arias","year":"2014","journal-title":"Elife"},{"key":"10.1016\/j.coviro.2016.05.004_bib0830","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1093\/jac\/dku209","article-title":"Mutations in the chikungunya virus non-structural proteins cause resistance to favipiravir (T-705), a broad-spectrum antiviral","volume":"69","author":"Delang","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.coviro.2016.05.004_bib0835","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1017\/dmp.2014.151","article-title":"Favipiravir: a new medication for the Ebola virus disease pandemic","volume":"9","author":"Nagata","year":"2015","journal-title":"Disaster Med Public Health Prep"},{"key":"10.1016\/j.coviro.2016.05.004_bib0840","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1126\/science.177.4050.705","article-title":"Broad-spectrum antiviral activity of Virazole: 1-beta-d-ribofuranosyl-1,2,4-triazole-3-carboxamide","volume":"177","author":"Sidwell","year":"1972","journal-title":"Science"},{"key":"10.1016\/j.coviro.2016.05.004_bib0845","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/nature14008","article-title":"Structure of influenza A polymerase bound to the viral RNA promoter","volume":"516","author":"Pflug","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2016.05.004_bib0850","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/nature14009","article-title":"Structural insight into cap-snatching and RNA synthesis by influenza polymerase","volume":"516","author":"Reich","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2016.05.004_bib0855","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/nature05379","article-title":"The mechanism by which influenza A virus nucleoprotein forms oligomers and binds RNA","volume":"444","author":"Ye","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2016.05.004_bib0860","doi-asserted-by":"crossref","first-page":"15366","DOI":"10.1073\/pnas.1107906108","article-title":"Inhibition of influenza virus replication via small molecules that induce the formation of higher-order nucleoprotein oligomers","volume":"108","author":"Gerritz","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coviro.2016.05.004_bib0865","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/nbt.1638","article-title":"Identification of influenza A nucleoprotein as an antiviral target","volume":"28","author":"Kao","year":"2010","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.coviro.2016.05.004_bib0870","doi-asserted-by":"crossref","first-page":"19151","DOI":"10.1073\/pnas.1013592107","article-title":"High-throughput identification of compounds targeting influenza RNA-dependent RNA polymerase activity","volume":"107","author":"Su","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coviro.2016.05.004_bib0875","doi-asserted-by":"crossref","first-page":"16515","DOI":"10.1073\/pnas.1113107108","article-title":"E339\u2026R416 salt bridge of nucleoprotein as a feasible target for influenza virus inhibitors","volume":"108","author":"Shen","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coviro.2016.05.004_bib0880","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1128\/AAC.02335-12","article-title":"Structure-based discovery of the novel antiviral properties of naproxen against the nucleoprotein of influenza A virus","volume":"57","author":"Lejal","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2016.05.004_bib0885","doi-asserted-by":"crossref","first-page":"e1005062","DOI":"10.1371\/journal.ppat.1005062","article-title":"A novel antiviral target structure involved in the RNA binding, dimerization, and nuclear export functions of the influenza A virus nucleoprotein","volume":"11","author":"Kakisaka","year":"2015","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2016.05.004_sbref0890","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.sbi.2016.01.002","article-title":"Towards a structural understanding of RNA synthesis by negative strand RNA viral polymerases","volume":"36","author":"Reguera","year":"2016","journal-title":"Curr Opin Struct Biol"},{"key":"10.1016\/j.coviro.2016.05.004_bib0895","doi-asserted-by":"crossref","first-page":"6668","DOI":"10.1021\/jm5007275","article-title":"Discovery of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of influenza PB2","volume":"57","author":"Clark","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.coviro.2016.05.004_bib0900","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1128\/AAC.04623-14","article-title":"Preclinical activity of VX-787, a first-in-class, orally bioavailable inhibitor of the influenza virus polymerase PB2 subunit","volume":"59","author":"Byrn","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2016.05.004_bib0905","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.antiviral.2016.01.012","article-title":"Meeting report: 4th ISIRV antiviral group conference: novel antiviral therapies for influenza and other respiratory viruses","volume":"129","author":"McKimm-Breschkin","year":"2016","journal-title":"Antivir Res"},{"key":"10.1016\/j.coviro.2016.05.004_bib0910","doi-asserted-by":"crossref","first-page":"e1002831","DOI":"10.1371\/journal.ppat.1002831","article-title":"Structural analysis of specific metal chelating inhibitor binding to the endonuclease domain of influenza pH1N1 (2009) polymerase","volume":"8","author":"Kowalinski","year":"2012","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2016.05.004_bib0915","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1128\/AAC.38.12.2827","article-title":"Inhibition of cap (m7GpppXm)-dependent endonuclease of influenza virus by 4-substituted 2,4-dioxobutanoic acid compounds","volume":"38","author":"Tomassini","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2016.05.004_bib0920","doi-asserted-by":"crossref","first-page":"e1002830","DOI":"10.1371\/journal.ppat.1002830","article-title":"Structural and biochemical basis for development of influenza virus inhibitors targeting the PA endonuclease","volume":"8","author":"DuBois","year":"2012","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2016.05.004_bib0925","doi-asserted-by":"crossref","first-page":"10524","DOI":"10.1128\/JVI.00832-13","article-title":"Mutational analysis of the binding pockets of the diketo acid inhibitor L-742,001 in the influenza virus PA endonuclease","volume":"87","author":"Stevaert","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2016.05.004_bib0930","doi-asserted-by":"crossref","first-page":"e1000362","DOI":"10.1371\/journal.pmed.1000362","article-title":"Efficacy of oseltamivir\u2013zanamivir combination compared to each monotherapy for seasonal influenza: a randomized placebo-controlled trial","volume":"7","author":"Duval","year":"2010","journal-title":"PLoS Med"},{"key":"10.1016\/j.coviro.2016.05.004_bib0935","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.antiviral.2012.08.002","article-title":"Oseltamivir\u2013zanamivir bitherapy compared to oseltamivir monotherapy in the treatment of pandemic 2009 influenza A(H1N1) virus infections","volume":"96","author":"Escuret","year":"2012","journal-title":"Antivir Res"},{"key":"10.1016\/j.coviro.2016.05.004_bib0940","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1128\/AAC.00933-09","article-title":"Effects of the combination of favipiravir (T-705) and oseltamivir on influenza A virus infections in mice","volume":"54","author":"Smee","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2016.05.004_bib0945","doi-asserted-by":"crossref","first-page":"e101325","DOI":"10.1371\/journal.pone.0101325","article-title":"Combination effects of peramivir and favipiravir against oseltamivir-resistant 2009 pandemic influenza A(H1N1) infection in mice","volume":"9","author":"Park","year":"2014","journal-title":"PLOS ONE"},{"key":"10.1016\/j.coviro.2016.05.004_bib0950","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1128\/AAC.01579-07","article-title":"Oseltamivir\u2013ribavirin combination therapy for highly pathogenic H5N1 influenza virus infection in mice","volume":"52","author":"Ilyushina","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2016.05.004_bib0955","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1177\/135965350701200302","article-title":"Amantadine\u2013oseltamivir combination therapy for H5N1 influenza virus infection in mice","volume":"12","author":"Ilyushina","year":"2007","journal-title":"Antivir Ther"},{"key":"10.1016\/j.coviro.2016.05.004_bib0960","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1128\/AAC.01012-08","article-title":"Effects of double combinations of amantadine, oseltamivir, and ribavirin on influenza A (H5N1) virus infections in cell culture and in mice","volume":"53","author":"Smee","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2016.05.004_bib0965","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1016\/S0140-6736(13)61125-3","article-title":"Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance","volume":"381","author":"Hu","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.coviro.2016.05.004_sbref0970","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.coviro.2014.04.009","article-title":"The epidemiology and spread of drug resistant human influenza viruses","volume":"8","author":"Hurt","year":"2014","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.coviro.2016.05.004_bib0975","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1021\/ml2000627","article-title":"Design and synthesis of benzenesulfonamide derivatives as potent anti-influenza hemagglutinin inhibitors","volume":"2","author":"Tang","year":"2011","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.coviro.2016.05.004_bib0980","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1021\/id500022h","article-title":"A potent anti-influenza compound blocks fusion through stabilization of the prefusion conformation of the hemagglutinin protein","volume":"1","author":"White","year":"2015","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.coviro.2016.05.004_bib0985","doi-asserted-by":"crossref","first-page":"29798","DOI":"10.1074\/jbc.M109.029470","article-title":"Thiazolides, a new class of anti-influenza molecules targeting viral hemagglutinin at the post-translational level","volume":"284","author":"Rossignol","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1016\/j.coviro.2016.05.004_bib0990","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.antiviral.2013.06.005","article-title":"The influenza virus NS1 protein as a therapeutic target","volume":"99","author":"Engel","year":"2013","journal-title":"Antivir Res"}],"container-title":["Current Opinion in Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625716300487?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625716300487?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,2]],"date-time":"2022-07-02T03:34:21Z","timestamp":1656732861000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879625716300487"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":99,"alternative-id":["S1879625716300487"],"URL":"https:\/\/doi.org\/10.1016\/j.coviro.2016.05.004","relation":{},"ISSN":["1879-6257"],"issn-type":[{"value":"1879-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current and novel antiviral strategies for influenza infection","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coviro.2016.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}